Find out how NAMs are influencing safety assessments and decision-making in the pharmaceutical industry ahead of 2026.

The FDA granted orphan drug designation to zavabresib, an investigational therapy for the treatment of myelofibrosis, a rare ...

Overview AI is speeding up drug discovery by analyzing large biological and chemical data in a short time.Deep learning and AI systems help design new drug mole ...

A large share of medicines developed today may never reach patients for a surprisingly simple reason: they cannot dissolve well enough in water. For most treatments, the oral route remains the gold ...

The FDA and EMA have aligned on ten guiding principles for the responsible use of artificial intelligence across the drug development lifecycle, establishing a shared framework to support innovation, ...

A top federal health official is again touting the therapeutic “promise” of psychedelics such as psilocybin and MDMA—though ...

The Union Health Ministry has amended the NDCT Rules, 2019 to reduce regulatory burden, waive permissions for low-risk ...

Lantern showcases two commercially ready, machine learning platforms that have the potential to accelerate drug discovery from months to days and dramatically reduce costs. predictBBB.ai and LBx-AI, ...

The Union Ministry of Health and Family Welfare has taken a series of measures including simplification of regulatory ...

The field of cancer research has increasingly focused on the metabolic underpinnings of tumorigenesis, recognizing how the reprogramming of cellular energy ...

Patient Integration is increasingly urgent in oncology research, as growing complexity fuels demand for patient-level translation and outcomes that reflect real needs across preclinical and clinical ...